NLRP3 and myocardial ischemia: Furthermore, NLRP3 inhibitors and different doses of MSMYA can decrease LDH levels and infarct size in varying degrees, reduce intracellular edema, mitochondrial swelling, and cristae rupture, as well as improving myofibrillar arrangement, indicating that MSMYS can relieve myocardial ischemia/reperfusion injury by improving cardiac structure.